Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;85(4):528-531.
doi: 10.1053/j.ajkd.2024.10.008. Epub 2024 Dec 18.

Glucocorticoid Exposure and Infection in Children and Adults With Glomerular Disease: Findings From the Cure Glomerulonephropathy Study

Dorey A Glenn  1 , Calvin Andrews  2 , Qian Liu  3 , Jarcy Zee  4 , Sarah Mansfield  2 , Abigail Smith  2 , Michelle M O'Shaughnessy  5 , Andrew Bomback  6 , Keisha Gibson  7 , Larry A Greenbaum  8 , Ronald J Falk  7 , Susan L Hogan  7 , Amy Mottl  7 , Michelle R Denburg  4 ; CureGN Consortium
Collaborators, Affiliations

Glucocorticoid Exposure and Infection in Children and Adults With Glomerular Disease: Findings From the Cure Glomerulonephropathy Study

Dorey A Glenn et al. Am J Kidney Dis. 2025 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Hazard of first infection-related acute care event among all participants (fully adjusted marginal structural model; adjusted for age, time from biopsy to study enrollment, sex, race, glomerular disease subtype, estimated glomerular filtration rate, comorbid conditions, and time-varying markers of disease activity [urinary protein-creatinine ratio and serum albumin]). GC, glucocorticoid; IS, immunosuppression. Low dose: ≤7.5 mg/d if ≥30 kg or <0.2 mg/kg/d if <30 kg. Medium dose: >7.5 mg/d and ≤30 mg/d if ≥30 kg or ≥0.2 mg/kg/d and ≤1 mg/kg/d if <30 kg. High dose: >30 mg/d if ≥30 kg or >1 mg/kg/d if <30 kg.
Figure 2.
Figure 2.
Percent follow-up time and rate of infection-related acute care events per 100 person-years, stratified by glucocorticoid dose exposure level. Low dose: ≤7.5 mg/d if ≥30 kg or <0.2 mg/kg/d if <30 kg. Medium dose: >7.5 mg/d and ≤30 mg/d if ≥30 kg or ≥0.2 mg/kg/d and ≤1 mg/kg/d if <30 kg. High dose: >30 mg/d if ≥30 kg or >1 mg/kg/d if <30 kg. IS, immunosuppression.
See this image and copyright information in PMC

References

    1. Glenn DA, Henderson CD, O’Shaughnessy M, et al. Infection-related acute care events among patients with glomerular disease. Clin J Am Soc Nephrol. 2020;15(12):1749–1761. doi: 10.2215/CJN.05900420 - DOI - PMC - PubMed
    1. Carter SA, Lightstone L, Cattran D, et al. A core outcome set for trials in glomerular disease: a report of the Standardized Outcomes in Nephrology–Glomerular Disease (SONG-GD) stakeholder workshops. Clin J Am Soc Nephrol. 2022;17(1):53–64. doi:10.2215/CJN.07840621 - DOI - PMC - PubMed
    1. Ponticelli C, Locatelli F. Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls. Clin J Am Soc Nephrol. 2018;13(5):815–822. doi:10.2215/CJN.12991117 - DOI - PMC - PubMed
    1. Glenn DA, Zee J, Mansfield S, et al. Immunosuppression exposure and risk of infection-related acute care events in patients with glomerular disease: an observational cohort study. Kidney Med. 2022;4(11):100553. doi:10.1016/j.xkme.2022.100553 - DOI - PMC - PubMed
    1. Mariani LH, Bomback AS, Canetta PA, et al. CureGN study rationale, design, and methods: establishing a large prospective observational study of glomerular disease. Am J Kidney Dis. 2019;73(2):218–229. doi:10.1053/j.ajkd.2018.07.020 - DOI - PMC - PubMed

LinkOut - more resources